Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption' Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken and failing its intended purpose.
Roche Bets Big On Alzheimer’s Prevention With New Trial As Duchenne Drug Setback Looms The pharma company is advancing a third late-stage study of its experimental Alzheimer’s drug trontinemab, which uses brain shuttle technology to bypass the blood-brain barrier and clear amyloid buildup.
Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in treatment as well.
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
5 Dividend Stocks to Hold for the Next 20 Years Discover five unstoppable dividend stocks that could pay you for life, and why I wouldn't sell any of them!
Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the American market.
3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon.
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline.
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.
2 Vanguard ETFs That Can Turn $400 per Month Into Over $1.7 Million Exchange-traded funds (ETFs) can be a lucrative source of wealth for patient investors.
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
5 Monster Stocks to Hold for the Next 25 Years Buy-and-hold investing only works if you choose the right companies. Here are some potential examples.
